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Steve Horvath1,2I recently described an epigenetic biomarker of aging
based on DNA methylation (DNAm) levels [1]. Unfortu-
nately, I made a software coding error in my analysis of
the cancer data, but not of the non-cancer tissue data.
The error effectively added an offset term to the age esti-
mates. All of my results from [1] that involve non-
cancerous tissue or cancer cell lines remain valid but I
have to report some corrections for the cancer tissue
data. In particular, I have to retract the statement that
cancer is associated with an increased DNA methylation
age (i.e. positive age acceleration) in most cancer types.
In fact, while some cancer types show positive age accel-
eration, others exhibit negative age acceleration. I deeply
regret this software coding error. The error arose from
me using the wrong age calibration function for the can-
cer tissue data sets, which led to a systematic over-
estimation of DNA methylation age (Figure 1).
Fortunately, all of the other statements about cancer
remain intact since the coding error effectively added an
offset term to predicted age that changed little with
chronological age (Figure 1). I am comforted by the fact
that most of the reported results for cancer become even
more significant, including the following. First, the re-
sults for cancer tissues are now more congruent with
those obtained for cancer cell lines (which remain un-
changed). Second, the age predictor leads to a much
lower error in cancer tissues (now 16 years). Third, the
results for TP53 become more significant, that is TP53
mutations are associated with lower age acceleration in
colorectal cancer.
As a result of this error, the following Figures and
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(http://creativecommons.org/publicdomain/ze Figure seven in the original publication; Figure 2
here: Age acceleration versus number of somatic
mutations in the TCGA data.
 Figure eight in the original publication; Figure 3
here: Age acceleration in breast cancer.
 Figure nine in the original publication; Figure 4 here:
Age acceleration in colorectal cancer, glioblastoma
multiforme and acute myeloid leukemia.
 Additional file twelve in the original publication;
Additional file 1 here: Description of cancer data sets.
 Additional file thirteen in the original publication;
Additional file 2 here: DNAm versus chronological
age in cancer.
 Additional file fourteen in the original publication;
Additional file 3 here: Age acceleration versus tumor
grade and stage.
 Additional file fifteen in the original publication;
Additional file 4 here: Age acceleration versus
mutation count status in breast cancer.
 Additional file sixteen in the original publication;
Additional file 5 here: Selected significant gene
mutations versus age acceleration.
 Additional file seventeen in the original publication;
Additional file 6 here: Effect of TP53 mutation on
age acceleration.
Below, for sections of the original paper that are af-
fected by the error, I explain how the corrected results
are different from those that were reported.DNAm age of cancer tissue versus tumor
morphology
In the original paper, I reported the correlation between
DNAm age and chronological age as being 0.15 (P =
1.0×10−29). The correct correlation is 0.16 (p = 2.5×10−33;
Additional file 2A). In addition, I reported that each
cancer/affected tissue shows evidence of significant age
acceleration. Instead, out of 20 cancer/affected tissues,
only 6 exhibit positive age acceleration effects while othersis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0) which permits unrestricted use, distribution, and reproduction
properly credited. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.






























Figure 1 Evaluating the effect of the error on the DNAm age estimate in the cancer samples. The old, incorrect estimate of DNAm age (y-axis)
versus the correct estimate (x-axis). Note that the two estimates are highly correlated (r = 0.98), which explains why most results are unaffected,
but the old estimate is poorly calibrated, which leads to an average bias of 42 years. After using the correct estimate, I can no longer observe a
positive age acceleration effect in cancer.
Figure 2 Age acceleration versus number of somatic mutations in the TCGA data. Mutation data from TCGA were used to count the number of
mutations per cancer sample. A) Age acceleration versus (log transformed) mutation count per sample across all cancers. Note that this analysis is
confounded by cancer/tissue type. B-P) A significant negative relationship between age acceleration and number of somatic mutations can be
observed in the following seven affected tissues/cancers: C) bone marrow (AML), D) breast carcinoma (BRCA), G) kidney (KIRC), H) kidney (KIRP),
K) ovarian cancer (OVAR), L) prostate (PRAD), and O) thyroid (THCA). No significant relationship could be found in the following six cancer types:
F) colon carcinoma (COAD), I) lung adenocarcinoma (LUAD), J) lung squamous cell carcinoma (LUSC), P) uterine endometrioid, M) rectal cancer
(READ), N) skin. Due to the low sample size, the results are inconclusive for B) bladder cancer and E) cervical cancer. Each point corresponds to a
DNA methylation sample (cancer sample from a human subject) analogous to Additional file 1. The x-axis reports the log transformed (base 10)
number of mutations observed per sample. The figure titles report the biweight midcorrelation, which is a robust measure of correlation.
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Figure 3 Age acceleration in breast cancer. Panels in the first column (A,E,I,M) show that estrogen receptor positive breast cancer samples have
increased age acceleration in four independent data sets. Panels in the second column (B,F,J) show the same result for progesterone receptor
positive cancers. Panels in the third columns (C,G,K) show that HER2/neu amplification is not associated with age acceleration. Panels in the
fourth column (D,H,L) show how combinations of these genomic aberrations affect age acceleration. N) Age acceleration across the following
breast cancer types: Basal-like, HER2-type, luminal A, luminal B, and healthy (normal) breast tissue. O) Ki-67 expression versus age acceleration.
P) Tumor grade is not significantly related to age accelerations reflecting results from Additional file 3. Vertical grey numbers on the x-axis report
sample sizes. The figure titles report the data source (GSE identifier from GEO or TCGA), and the Kruskal Wallis test p-value (except for panels O
and P which report correlation test p-values).
Horvath Genome Biology  (2015) 16:96 Page 3 of 5often show negative age acceleration effects, i.e. they ap-
peared younger than expected (Figure 2B).
The following original statement remains unchanged:
“Tumor morphology (grade and stage) has only a weak
relationship with age acceleration in most cancers: only
4 out of 33 hypothesis tests led to a nominally (p < 0.05)
significant result (Additional file 3)”.
But I have to retract the statement that only the nega-
tive correlation between stage and age acceleration in
thyroid cancer remains significant after a applying a
Bonferroni correction. It turns out that the uncorrected
p-value of 0.0048 (Additional file 3Z) is not significant
after multiplying it by 33.Cancer tissues with high age acceleration exhibit fewer
somatic mutations
The original statement that the number of mutations
per cancer sample tends to be inversely correlated with
age acceleration (Figure 2A) remains unchanged.
But I have to retract the claim that one can observe a
significant negative relationship between age accelerationand the number of somatic mutations in thyroid cancer
(Figure 2O).
TP53 mutations are associated with lower age
acceleration
Additional file 5 presents the genes whose mutation has
the strongest effect on age acceleration. The following
original statement remains unchanged: "Strikingly, TP53
was among the top 2 most significant genes in 4 out of
the 13 cancer data sets".
But I have to revise the following paragraph:
"Further, TP53 mutation is associated with significantly
lower age acceleration in five different cancer types in-
cluding AML (p = 0.0023), breast cancer (p = 1.4E-5 and
p = 3.7E-8), ovarian cancer (p = 0.03), and uterine corpus
endometrioid (p = 0.00093). Further, marginally signifi-
cant result can be observed in lung squamous cell car-
cinoma and colorectal cancer (p = 0.073, below). I could
only find one cancer type (GBM) where mutations in
TP53 are associated with a nominally significant in-
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Figure 4 Age acceleration in colorectal cancer, GBM and AML. A-F) report results for colorectal cancer. Mean age acceleration (y-axis) in
colorectal cancer versus mutation status (denoted by +) in A) BRAF, B) TP53, C) K-RAS. D) Promoter hyper methylation of the mismatch repair
gene MLH1 (denoted +) is significantly associated with age acceleration. E) Mean age acceleration across different patient groups defined by
combinations of BRAF, TP53, K-RAS, MLH1 status. The first bar reports the age acceleration in normal adjacent colorectal tissue from cancer
patients but the sample size of 4 is rather low. F) CpG island methylator phenotype is associated with age acceleration. G-R) present results for
various genomic abnormalities in glioblastoma multiforme. J) H3F3A mutations versus age acceleration. Samples with a G34R mutation have the
highest age acceleration. Panels S-W (last row) show results for various genomic aberrations in acute myeloid leukemia. X) Thyroid cancer age
acceleration versus RAS family mutation status is inconclusive since mutation status was largely unknown.
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acceleration in six data sets (Additional file 6) including
AML (P = 0.0041), breast cancer (P = 7.8×10−12 and P =
1.4×10−12), ovarian cancer (P = 0.04), uterine corpus endo-
metrioid (P = 0.0012), and colorectal cancer (P = 0.036,
Figure 4B). Further, marginally significant result can be
observed in lung squamous cell carcinoma (P = 0.088
Additional file 6G).
Somatic mutations in steroid receptors accelerate DNAm
age in breast cancer
The following original statement remains unchanged:
“Age acceleration differs greatly across different breast
cancer types (Figure 4N): Luminal A tumors (typically
ER+ or PR+, HER2-, low Ki67), show the highest posi-
tive age acceleration”.
But I retract the statement that luminal B tumors (typically
ER+ or PR+, HER2+ or HER2- with high Ki67) show a simi-
lar effect.
Proto-oncogenes affect DNAm age in colorectal cancer
The p-value in the following statement "Echoing previ-
ous results, TP53 mutations appear to be associated withdecreased age acceleration (p = 0.073)" needs to be re-
vised to (p = 0.036, Figure 4B).
The p-value in the following statement "Promoter
hypermethylation of the mismatch repair gene MLH1
leads to the most significant increase in age acceleration
(P = 5.7×10−5)" needs to be revised to (p = 3.9×10−7,
Figure 4D).
The p-value in the following statement "The CpG is-
land methylator phenotype, defined by exceptionally
high cancer-specific DNA hypermethylation, is also sig-
nificantly (p = 3.5×10−5) associated with age acceleration"
needs to be revised to (p = 3.6×10−7, Figure 4F).DNAm age in glioblastoma multiforme (GBM)
The p-value in the following statement "Interestingly,
age acceleration in GBM samples is highly significantly
(p = 3.3×10−7) associated with certain mutations in
H3F3A" needs to be revised to (p = 0.0015, Figure 4J).
The p-value in the following statement "…age acceler-
ation varies significantly (p = 2×10−7) across the GBM
subtypes defined in (Sturm et al 2012)" needs to be re-
vised to (p = 1.2×10−7, Figure 4L).
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The following statement remains unchanged: “Mutations
in FLT3, RAS, NPMc, and various well characterized
translocations do not seem to relate to age acceleration
in AML samples”.
But I have to retract the claim that mutations in IDH1
do not relate to age acceleration. Rather, IDH1 muta-
tions are nominally significantly related with age acceler-
ation (p = 0.036, Figure 4S).
DNAm age of cancer cell lines
My original results for cancer cell lines were not affected
by the coding error;that is, they remain correct.
Conclusions
My conclusion section remains largely unchanged. But I
have to revise the following sentence: "While all cancer
tissues exhibit signs of severe age acceleration, this is
not necessarily the case for individual cancer cell lines".
It turns out that cancer types are similar to individual
cancer cell lines. Some cancer types exhibit positive age
acceleration effects (e.g. luminal breast cancer) while
others exhibit negative age acceleration (e.g. basal breast
cancer, Figure 3N).
Additional files
Additional file 1: Description of cancer data sets. The file describes
32 publicly available cancer tissue data sets and 7 cancer cell line data
sets. Column 1 reports the data number and corresponding color code.
Other columns report the affected tissue, Illumina platform, sample size n,
proportion of females, median age, age range (minimum and maximum
age), relevant citation (TCGA or first author with publication year), and
public availability. None of these data sets were used in the construction
of estimator of DNAm age. The table also reports the age correlation,
cor(Age,DNAmage), median error, and median age acceleration.
Additional file 2: DNAm age versus chronological age in cancer.
Each point corresponds to a DNA methylation sample (cancer sample
from a human subject). Points are colored and labelled according to the
underlying cancer data sets as described in Additional file 1. A) Across all
cancer data sets, there is only a weak correlation (cor=0.16, p=2.5E-33)
between DNAm age (x-axis) and chronological patient age (y-axis). B)
Mean age acceleration (y-axis) versus cancer type. C-W) Results for
individual cancers/affected tissues. Several cancer tissues maintain moderately
large age correlations including E) brain, U) thyroid, K,L) kidney, M) liver,
I) colorectal, and F) breast cancer.
Additional file 3: Age acceleration versus tumor grade and stage.
Panels correspond to the cancer data sets described in Additional file 1.
Nominally significant negative correlations between grade and age
acceleration can be observed in ovarian serous cystadenocarcinoma
(panel G) and uterine corpus endometroids (panel J). A nominally
significant positive correlation between stage and age acceleration can
be observed for colon adenocarcinoma (panel O). (Z) A significant
negative correlation between stage and age acceleration can be
observed in thyroid cancer. Since grade and stage are often considered
as ordinal variables, correlation test p-values are reported in all panels
except the last. H) For prostate cancer, the x-axis reports the Gleason sum
score. The last panel shows that mean age acceleration in acute myeloid
leukemia is not significantly related to French American British (FAB)
morphology but some groups (notably M6 and M7) are very small
(rotated grey numbers).Additional file 4: Age acceleration versus mutation count status in
breast cancer. Mutation count status (x-axis) was defined by assigning
tumor samples to the high mutation count group if their number of
somatic mutations was larger than 50. Other thresholds lead to similar
results. A-F) and G-L) report findings for Illumina 27K and 450K data,
respectively. A, G) The barplots show that mean age acceleration (y-axis)
is lower in breast cancer samples with high mutation count (compared
to those samples whose somatic mutation count is less than 50). This
result can also be found in ER+ (panels B,H), ER- (C,I), PR+ (D,J), PR- (E,K),
and triple negative (F,L) breast cancer samples.
Additional file 5: Selected significant gene mutations versus age
acceleration. The TCGA data sets were stratified by cancer type and
Illumina platform. Mean age acceleration (y-axis) versus mutation status
(x-axis) for up to two of the most significant genes per data set. Note
that age acceleration in bone marrow (AML) was most highly related to
mutation in the following 2 genes: PHF6 and TP53. Age acceleration in
the two breast cancer data was most highly related to mutations in
GATA3, TP53, and TTN. Strikingly, TP53 was among the top 2 most
significant mutated genes in four out of 13 cancer data sets.
Additional file 6: Effect of TP53 mutation on age acceleration.
Mutations in TP53 are associated with significantly lower age acceleration in
5 cancers: including AML, breast cancer, ovarian serous cystadenocarcinoma,
and uterine corpus endometrioid. Marginally significant results could be
observed in lung squamous cell carcinoma (p=0.088 for the 27K data but
not for the 450K data).
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